Atrial Fibrillation and Carotid Atherosclerosis in Ischemic Stroke Patients-(AFCAS)

Atrial Fibrillation Clinical Trial

— AFCAS  

Official title:

Carotid Artery Atherosclerosis in Ischemic Stroke Patients With Atrial Fibrillation.(Atrial Fibrillation and Carotid Atherosclerosis in Ischemic Stroke Patients- AFCAS)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04821700
• Other study ID #: AFCAS 2021
• Status: Active, not recruiting
• Start date: March 20, 2020
• Est. completion date: April 5, 2021

Study information

• Verified date: March 2021
• Source: University of Thessaly
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The main aim of the study is to investigate the prevalence and characteristics of ischemic stroke patients with atrial fibrillation and concurrent carotid atherosclerosis. Additionally, this study will investigate the effect of concurrent carotid atherosclerosis on the outcomes of recurrent stroke, myocardial infarction and death during follow-up

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3000
• Est. completion date: April 5, 2021
• Est. primary completion date: March 25, 2021
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Hospitalization due to ischemic stroke
• Atrial fibrillation
• ?ny type of carotid vascular imaging

Exclusion Criteria:

• Intracerebral haemorrhage on admission
• Haemorrhagic transformation on admission

Related Conditions & MeSH terms

• Atherosclerosis
• Atrial Fibrillation
• Carotid Artery Diseases
• Carotid Stenosis
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Biological:
• Carotid Stenosis
To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation

Locations

Country	Name	City	State
Greece	Medical School, University of Thessaly, Larissa University Hospital	Larissa

Sponsors (1)

Lead Sponsor	Collaborator
University of Thessaly

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stroke recurrence		From date of randomization until the date of stroke recurrence, assessed up to 60 months
Primary	Myocardial infarction		From date of randomization until the date of myocardial infarction, assessed up to 60 months
Primary	Death during follow-up		From date of randomization until the date of death from any cause, assessed up to 60 months
Secondary	modified Rankin Scale at 3 months	mRS: modified Rankin Scale; 0=No symptoms at all; 1=No significant disability despite symptoms: able to carry out all usual duties and activities; 2=Slight disability: unable to carry out all previous activities, but able to look after own affairs without assistance; 3= Moderate disability: requiring some help, but able to walk without assistance; 4=Moderately severe disability: unable to walk without assistance and unable to attend to own bodily needs without assistance; 5=Severe disability: bedridden, incontinent and requiring constant nursing care and attention; 6=Dead	3 months